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Abstract
 
It has been demonstrated that vascular endothelial cell growth factor (VEGF) induction of
angiogenesis requires activation of the nuclear factor of activated T cells (NFAT). We show
that NFATc2 is also activated by basic fibroblast growth factor and blocked by the inhibitor of
angiogenesis pigment epithelial–derived factor (PEDF). This suggests a pivotal role for this
transcription factor as a convergence point between stimulatory and inhibitory signals in the
regulation of angiogenesis.
We identified c-Jun NH
 
2
 
-terminal kinases (JNKs) as essential upstream regulators of NFAT
activity in angiogenesis. We distinguished JNK-2 as responsible for NFATc2 cytoplasmic retention
by PEDF and JNK-1 and JNK-2 as mediators of PEDF-driven NFAT nuclear export.
We identified a novel NFAT target, caspase-8 inhibitor cellular Fas-associated death domain–
like interleukin 1
 
 
 
–converting enzyme inhibitory protein (c-FLIP), whose expression was co-
regulated by VEGF and PEDF. Chromatin immunoprecipitation showed VEGF-dependent
increase of NFATc2 binding to the c-FLIP promoter in vivo, which was attenuated by PEDF.
We propose that one possible mechanism of concerted angiogenesis regulation by activators
and inhibitors may be modulation of the endothelial cell apoptosis via c-FLIP controlled by
NFAT and its upstream regulator JNK.
Key words: regulatory kinases • angiogenesis inhibitors • signaling cross-talk • transcription 
factors • pigment epithelial–derived factor
 
Introduction
 
Angiogenesis is regulated by the balance of extracellular in-
ducers and inhibitors (1). On the intracellular level, the effects
of pro- and antiangiogenic factors translate into molecular
events that lead to endothelial cell (EC) survival or apoptosis
(2). Situations in which the EC environment is populated
exclusively by inducers or by antiangiogenic molecules are
extremely rare. Thus, the cells are forced to resolve the bal-
ance between prosurvival and proapoptotic events, and the
outcome determines whether existing vasculature will expand,
remain the same, or regress (3). However, recent discoveries
indicate that simple balance does not adequately reflect the
course of events, and that the activated state of the endothe-
lium due to angiogenic stimuli is the necessary prerequisite
for the inhibitors to exert their activity (4, 5). Therefore,
pro- and antiangiogenic signals are likely to engage in cross-
talk with interdependent outcome.
We have recently uncovered one point where the stimu-
latory and inhibitory pathways overlap. Several angiogenic
stimuli cause elevated surface levels of CD95/Fas, a death
receptor, on the activated endothelium, whereas the pig-
ment epithelial–derived factor (PEDF), a potent antiangio-
genic factor, increases endothelial FasL. When simulta-
neous, these two molecular events initiate apoptosis; and,
thus, the cessation of angiogenesis (5). Here, we investi-
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Abbreviations used in this paper:
 
 bFGF, basic fibroblast growth factor; c-FLIP,
cellular Fas-associated death domain–like interleukin 1
 
 
 
–converting enzyme
inhibitory protein; ChIP, chromatin immunoprecipitation; EC, endothelial
cell; EMSA, electrophoresis mobility shift assay; HUVEC, human umbilical
vein endothelial cell; JNK, c-Jun NH
 
2
 
-terminal kinase; MAPK, mitogen-
activated protein kinase; PAb, polyclonal antibody; PEDF, pigment epithe-
lial–derived factor; TUNEL, TdT-mediated dUTP nick-end labeling;
VEGF, vascular endothelial cell growth factor. 
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gated molecules other than CD95 involved in the cross-
talk between angiogenic stimuli, vascular endothelial cell
growth factor (VEGF), or basic fibroblast growth factor
(bFGF), and inhibitory PEDF with an emphasis on the
stress-activated c-Jun NH
 
2
 
-terminal kinases (JNKs) and
NFAT, and their contribution to the outcome of angio-
genic switch, the balance between EC survival and apoptosis.
JNK-1 contributes to opposing biological functions, cell
proliferation, or cell death depending on the activation ki-
netics. Short and transient activation is usually associated
with cell death, whereas long, sustained activation leads to
proliferation (6, 7). In the ECs subjected to stress by serum
deprivation or by ceramide, VEGF inhibits rapid and tran-
sient JNK induction typical for apoptosis (8).
Signals generated during apoptosis alter the activity of
transcription factors via distinct transduction pathways.
Several trans-acting, DNA-binding proteins such as mem-
bers of Jun and NF-
 
 
 
B families are necessary for apoptosis
(7, 9), whereas NFAT family members are implicated in
survival (10–12). The NFAT family of transcription factors
encompasses five proteins related to the Rel/NF-
 
 
 
B family
(13–15). Cytosolic NFAT proteins are dephosphorylated
upon stimulation and shuttled to the nucleus to become
engaged in transcription (16, 17). This pathway is regulated
by the extracellular signals using NFAT kinases (18), some
of which are constitutively active, such as casein kinase 1
and glycogen synthase kinase-3, and maintain the inactive,
phosphorylated NFAT state in resting cells (19, 20). The
others are inducible, such as p38 and JNK. Both inducible
and constitutive kinases rephosphorylate activated NFAT
and cause its nuclear export (18, 21, 22).
NFAT is expressed in numerous cell types and contrib-
utes to diverse functions (23, 24). Importantly, NFATc2
activation was identified as a critical component of VEGF-
induced angiogenesis and linked to the induction of cy-
clooxygenase-2 (25), which is also a critical player in angio-
genesis (26, 27).
Our work identified NFATc2 as a crossing point for the
endothelial cell survival pathways initiated by proangiogenic
VEGF and bFGF and the inhibitory, proapoptotic factor
PEDF. We showed that PEDF activated JNK kinases in vas-
cular ECs. PEDF-dependent JNK activation restored NFATc2
phosphorylation and localization to the cytoplasm in ECs
activated by VEGF and bFGF. Neither JNK activation nor
NFAT activation blockade could be detected in nonstimu-
lated, resting ECs. JNK activation was crucial for PEDF inhib-
itory activity because SP600125, a generic inhibitor of JNK
kinases, reversed PEDF ability to induce EC apoptosis and to
block chemotaxis, and curtailed its antiangiogenic activity in
vivo. Finer dissection of NFATc2–JNK interactions induced
by PEDF in the activated endothelium showed that NFATc2
retention in the cytoplasm was solely due to JNK-2, whereas
NFAT nuclear export was driven by both JNK-1 and -2.
We identified a novel NFAT transcriptional target,
cellular FLICE inhibitory protein (cellular Fas-associated
death domain–like interleukin 1
 
 
 
–converting enzyme in-
hibitory protein [c-FLIP]), an endogenous dominant nega-
tive version of caspase-8, that mediates resistance to apop-
totic signaling (28). JNK activation by PEDF lead to
decrease in endothelial c-FLIP message and NFATc2 bind-
ing to c-FLIP endogenous promoter.
In summary, our findings showed that apoptosis and an-
giogenesis blockade by PEDF occurred in stimulated and
not in quiescent ECs and required phosphorylation of
NFATc2 by JNK-2 followed by sequestration to the cyto-
plasm, which precludes transcription of the target genes
that, like c-FLIP, are critical for the EC survival and angio-
genesis. This is the first mechanistic demonstration of the
overlap between the signaling pathways generated by an-
giogenesis inhibitors and stimuli.
 
Materials and Methods
 
Cell Culture, Antibodies, and Reagents.
 
Human umbilical vein
ECs (HUVECs; National Cancer Institute) and human microvas-
cular ECs (Clonetics Cell Systems) were grown to 90% conflu-
ence on gelatinized surface in MCDB131 medium (Sigma-
Aldrich) with growth supplements (bullet kit; BioWhittaker) in
5% CO
 
2
 
 at 37
 
 
 
C and used at passages 5–8.
We used rabbit polyclonal NFATc2 pAb 672 (J.M. Redondo,
Universidad Autonoma de Madrid, Madrid, Spain) for immuno-
blots and NFATc2 mouse mAb G1-D10 (Santa Cruz Biotech-
nology, Inc.) for immunostaining. Mouse anti–c-FLIP mAb G-11
and goat antiactin pAb I-19 were obtained from Santa Cruz Bio-
technology, Inc. Phospho-specific antibodies for the catalytic
core peptides of JNK or p38 were obtained from Promega. Rab-
bit phospho-Erk1/2 pAb were obtained from Biosource Interna-
tional. A mouse JNK1 mAb (BD Biosciences), rabbit anti-JNK/
SAPK1 pAb (Upstate Biotechnology), anti-Erk1/2 (Promega),
and anti-p38 (Santa Cruz Biotechnology, Inc.) were used to en-
sure equal loading. For immunoprecipitation, we used rabbit
phosphoserine pAb (Zymed Laboratories) and protein A/G aga-
rose (Santa Cruz Biotechnology, Inc.). Antibodies for GM130
Golgi matrix protein were obtained from Transduction Labs.
Fluorescent-labeled secondary antibodies were obtained from
Jackson ImmunoResearch Laboratories.
VEGF and bFGF were obtained from R&D Systems. His-
tagged recombinant human PEDF was isolated from the medium
conditioned by human embryonic kidney cells (29), and its activ-
ity was verified in the in vitro EC migration assay. GST-NFATc2
(1-418) cloned into pGEX2T vector was purified as described
previously (30). JNK inhibitor SP600125 (1,9-pyrazoloanthrone)
was obtained from Calbiochem. All other reagents were obtained
from Sigma-Aldrich.
 
Western Blotting. 
 
Cells were lysed in 50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 1% NP-40, and 0.5% sodium deoxycholate
with protease and phosphatase inhibitors, and extracts were incu-
bated for 20 min on ice and cleared by centrifugation. The sam-
ples were resolved by SDS-PAGE (30 
 
 
 
g/lane) and transferred
onto nitrocellulose membranes. Membranes were blocked in
Tris-buffered saline, pH 7.4, 0.1% Tween-20 with 5% blotto; in-
cubated overnight at 4
 
 
 
C with primary antibodies NFATc2
(1:3,000 dilution) and c-FLIP (1:1,000 dilution) in blocking buffer;
washed with Tris-buffered saline, pH 7.4, 0.1% Tween-20; and
incubated with horseradish peroxidase secondary antibodies. The
bands were visualized with Lumi-GLO chemiluminescent sub-
strate (KPL). Erk1/2, JNK, and p38 were detected as recom-
mended by Promega. 
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Subcellular fractionation was performed as described previ-
ously (31). In brief, 1.5 
 
 
 
 10
 
6
 
 ECs washed with cold PBS were
resuspended in 10 mM Hepes, 1.5 mM MgCl
 
2
 
, 10 mM KCl, 0.5
mM DTT, and protease/phosphatase inhibitors (200 
 
 
 
l/sample)
and incubated for 10 min on ice. Nuclei were pelleted, resus-
pended in 20 mM Hepes, 1.5 mM MgCl
 
2
 
, 420 mM NaCl, 0.2
mM EDTA, 0.5 mM DTT, 25% glycerol, and protease/phos-
phatase inhibitors (50 
 
 
 
l/sample), and incubated on ice for 20
min; extracts were cleared of debris. Equal cell number equiva-
lents of cytosolic and nuclear fractions were used.
 
Immunoprecipitation. 
 
Cell extracts precleared with protein A/G
agarose beads (1 h) were incubated overnight at 4
 
 
 
C with JNK-1
or JNK-2 antibodies, and complexes were washed three times
with lysis buffer and resolved by gradient SDS-PAGE. Western
blot was probed with NFATc2 antibody.
 
Substrate Phosphorylation. 
 
To measure kinase activity, cells
were lysed in 20 mM Hepes, pH 7.5, 10 mM EGTA, 1% NP-40,
2.5 mM MgCl
 
2
 
, 40 mM 
 
 
 
-glycerophosphate, 1 mM DTT, 2
mM Na
 
3
 
VO
 
4
 
, and protease inhibitors. Cells were solubilized on
ice for 60 min, and extracts were cleared by centrifugation and
incubated with JNK1 antibodies (Santa Cruz Biotechnology,
Inc.) and protein A/G agarose beads (4 h, 4
 
 
 
C). JNK complexes
recovered by centrifugation were washed with lysis buffer and re-
constituted in reaction buffer (20 mM Hepes, pH 7.5, 20 mM
MgCl
 
2
 
, 20 mM 
 
 
 
-glycerophosphate, and 2 mM DTT). Reaction
was held for 30 min at 30
 
 
 
C in 40 
 
 
 
l of final mix (30 
 
 
 
l JNK im-
munocomplexes, 250 
 
 
 
M of cold ATP, 10 
 
 
 
Ci of 
 
 
 
-[
 
32
 
P] ATP,
and 1 
 
 
 
g GST-NFATc2). The samples were run on 10% SDS-
PAGE, and the gels were dried and analyzed by autoradiography.
 
Immunofluorescence Analysis. 
 
The cells grown on gelatinized
coverslips in 24-well plates were fixed and permeabilized in 3.7%
paraformaldehyde, 0.2% Triton X-100 in PBS (10 min, room
temperature); blocked in 1% donkey serum (30 min, room tem-
perature); and incubated with NFATc2 mAb (1 
 
 
 
g/ml, 4
 
 
 
C
overnight). The coverslips were incubated with Cy2-labeled
donkey anti–mouse antibodies (30 min, room temperature),
washed and mounted in DPX medium. The images were ac-
quired by laser-scanning confocal microscopy, with a 100
 
 
 
 ob-
jective, 488 nm excitation, and 510 nm emission.
 
RT-PCR. 
 
Total RNA was extracted from ECs with TRI-
zol reagent (Life Technologies). 2 
 
 
 
g/sample was converted into
the cDNA template using a kit (Amersham Biosciences) and ana-
lyzed by semi-quantitative PCR. The amplification mixture (25
 
 
 
l final volume) contained 1 
 
  
 
Taq polymerase buffer, 0.2 mM
dNTPs, 1.5 mM MgCl
 
2
 
, 0.5 
 
 
 
M of each primer, and 2.5 U Taq
(Life Technologies). cDNA was equalized in 18-22 cycle amplifi-
cation reaction (1:1,000 template dilution) with 
 
 
 
-actin primers
5
 
 
 
-TGTTGGCGTACAGGTCTTTGC-3
 
 
 
 (forward) and 5
 
 
 
-
GCTACGAGCTGCCTGACGG-3
 
 
 
 (reverse), yielding a 182-
bp product. For c-FLIP, the following primers were used:
5
 
 
 
-GATGTCTGCTGAAGTCATCCATCA-3
 
 
 
 (forward) and
5
 
 
 
-CACTACGCCCAGCCTTTTGG-3
 
 
 
 (reverse), yielding a
1468-bp product. The number of cycles with c-FLIP primers
(denaturation, 30 s, 60
 
 
 
C; annealing, 30 s; and polymerization,
60 s) was chosen for the product amount to be in the linear range
with the template.
 
Apoptosis Assay. 
 
Cells plated on gelatinized coverslips in 24-
well plates (5 
 
 
 
 10
 
4
 
 cells/well) were fixed by adding buffered para-
formaldehyde to the culture medium to a final concentration of 1%.
Apoptotic cells were detected using TdT-mediated dUTP nick-end
labeling (TUNEL)–based ApopTag kit (Serological Corp.) follow-
ing the manufacturer’s instructions and counterstained with 50 
 
 
 
g/
ml propidium iodide. Quantitative analysis was performed with
MetaMorph software, and the percentage of TUNEL positive cells
was calculated in two to six randomly selected fields of the two dif-
ferent chambers (600–1,200 cells/condition).
 
Electrophoresis Mobility Shift Assay (EMSA). 
 
Nuclear extracts
were prepared as described previously (32). 1.5 
 
 
 
 10
 
6
 
 HUVECs
washed in PBS were lysed in ice-cold hypotonic buffer (10 mM
NaCl). Released nuclei were incubated for 30 min on a rocking
platform in hypertonic buffer (400 mM NaCl), centrifuged for 10
min at 15,000 
 
g
 
, and extracts were immediately frozen and stored
at 
 
 
 
80
 
 
 
C. 2 
 
 
 
g nuclear proteins were incubated for 10 min on
ice with 1 
 
 
 
g poly dI-dC in 4 
 
 
 
l 5
 
 
 
 DNA-binding buffer (10%
polyvinylethanol, 12.5% glycerol, 50 mM Tris, pH 8.0, 2.5 mM
EDTA, and 2.5 mM DTT). 
 
32
 
P-labeled double-stranded oligo-
nucleotide (5 
 
 
 
 10
 
7
 
–10
 
8
 
 cpm/
 
 
 
g) was added to a final concen-
tration 1 ng/
 
 
 
l, and the reaction was continued for 30 min. For
the competition, labeled probes were added 30 min after the 10-
fold molar excess unlabeled oligonucleotide. For supershifts, pre-
immune serum or NFATc2 pAb 672 were added. DNA–protein
complexes were resolved on 4% nondenaturing PAAG. The fol-
lowing probes were used: SP1, 5
 
 
 
-ATTCGATCGGGGCG-
GGGCGAGC-3
 
 
 
 (33); and NFAT, 5
 
 
 
-ACGCCCAAAGAGGA-
AAATTTGTTTCATACA-3
 
 
 
 (34).
 
Chromatin Immunoprecipitation (ChIP) Assay.
 
The ChIP assay
was performed with the kit obtained from Upstate Biotechnol-
ogy using the manufacturer’s protocol with minor adjustments.
HUVECs were grown to confluence, and formaldehyde was
added directly to culture medium to a final concentration of 1%
(20 min, 37
 
 
 
C). The cells were washed at 4
 
 
 
C in PBS, lysed for
10 min in 1% SDS, 10 mM Tris HCl, pH 8.0. The lysates were
sonicated (10 s, three times; Branson Sonifier 450), and the debris
was removed by centrifugation. Sonication was optimized to
produce average DNA fragments of 1 kb. Aliquots were taken to
control DNA input, the remainder diluted 10 times in 0.01%
SDS, 1% Triton X-100, 1 mM EDTA, 10 mM Tris HCl, pH
8.0, and 150 mM NaCl, phosphatase/protease inhibitors, and in-
cubated overnight (4
 
 
 
C) with NFATc2 pAb 672 or control rab-
bit IgG (Santa Cruz Biotechnology, Inc.). DNA–protein com-
plexes were isolated on salmon sperm DNA linked to protein A
agarose beads and extracted with 1% SDS, 0.1 M NaHCO
 
3
 
.
Cross-linking was reversed at 65
 
 
 
C for 5 h, and proteins were re-
moved with proteinase K and extracted with phenol/chloroform
DNA redissolved and PCR-amplified with c-FLIP promoter
primers, 5
 
 
 
-TCACGTTTGCTATGACTCCCAGAC-3
 
 
 
 (for-
ward); and 5
 
 
 
-TCCACGCGTTAGGAGTAAACACTG-3
 
 
 
 (re-
verse), product length of 382 bp.
 
Corneal Neovascularization Assay.
 
The assay was performed as
described previously (35). Hydron-sucralfate pellets (
 
 
 
1 
 
 
 
l) were
implanted into the cornea of anesthetized C57/Bl6 mice (Jackson
ImmunoResearch Laboratories) 0.5–1.0 mm from the limbus.
Pellets contained 50 ng bFGF, 200 ng PEDF, and 1 
 
 
 
M JNK in-
hibitor where indicated. On day 6, the eyes were scored and
photographed, and capillaries growing from the limbus and
reaching the pellet were regarded as a positive response.
 
Statistical Analysis. 
 
Quantitative results are presented as mean
values 
 
 
 
 SD. Differences were analyzed by paired Student’s 
 
t 
 
test
and p-values 
 
 
 
0.05 were accepted as statistically significant.
 
Results
 
Angiogenesis Inducers Activate NFATc2 and Inhibitory
PEDF Cause NFATc2 Phosphorylation/Deactivation.
 
The
activation and subcellular distribution of NFAT family 
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members is determined by phosphorylation (36–38); NFAT
dephosphorylation/activation was shown previously to
mediate VEGF-induced angiogenesis (25). In addition to
reproducing results by Hernandez et al. (Fig. 1, b and c;
reference 25), we found that another inducer, bFGF, also
triggered NFATc2 dephosphorylation and nuclear transfer
(Fig. 1, a–d).
To determine if inhibitory PEDF influences NFAT acti-
vation dynamics, we analyzed NFATc2 phosphorylation by
immunoprecipitation with antibodies for phosphoserine
and Western blotting with NFATc2 antibody (Fig. 1 b).
Subcellular localization of NFATc2 was examined by indi-
rect immunofluorescence (Fig. 1, c and d). We found inac-
tive NFATc2 in resting ECs, as was reflected by high phos-
phorylation levels, and cytoplasmic localization in the
majority of the cells. The levels of phosphorylated NFATc2
dropped 4–7-fold upon VEGF stimulation and 8–20-fold
with bFGF (Fig. 1, a and b). In VEGF-stimulated ECs,
PEDF increased NFATc2 phosphorylation 
 
 
 
20-fold com-
pared with VEGF alone and 
 
 
 
10-fold compared with un-
treated control, but failed to affect NFATc2 activation
in nonstimulated cells (Fig. 1 b). In timed experiments,
NFATc2 phosphorylation due to PEDF reached maximum
as early as 15 min, persisted for 1 h, and subsided by 2 h of
treatment (unpublished data).
Phosphorylation changes were consistent with NFATc2
redistribution; upon stimulation, the percentage of ECs
with cytoplasmic NFAT localization decreased signifi-
cantly, and conversely, nuclear localization increased. PEDF
treatment restored NFATc2 localization to the cytoplasm
in the majority of stimulated cells (Fig. 1, c and d).
 
NFAT Blockade by PEDF Required JNK, But Not Erk-1/2
or p38 Mitogen-activated Protein Kinases (MAPKs).
 
To fur-
ther elucidate mechanisms of NFAT regulation by PEDF,
we examined MAP kinases, a common denominator in the
mitogenesis by multiple angiogenic stimuli (39, 40) as pos-
sible upstream modifiers of NFAT activity (18). Western
blots of the cell extracts that probed for active phosphory-
lated Erk-1/2 active phosphorylated p38 showed no signif-
icant changes in their activation state due to PEDF (Fig. 2 a).
In contrast, PEDF changed JNK activity. Although there
was no effect due to PEDF in resting ECs, in stimulated
cells, it strongly augmented the increase in JNK activity
caused by VEGF or bFGF alone (Fig. 2 b). Western blot-
ting with the antibodies against active, dually phosphory-
lated JNK showed activation of the two JNK isoforms
likely corresponding to the JNK-1 and JNK-2 (Fig. 2 b).
After 15 min of stimulation with VEGF or bFGF, JNK ac-
tivity was increased two- to fourfold (Fig. 2 b, top). PEDF
had no effect on JNK phosphorylation in nonstimulated
ECs, but augmented JNK activation by angiogenic stimuli
(Fig. 2 b, top). Both JNK activation by VEGF and its
PEDF-dependent increase persisted for 1 h (unpublished
data). Consistent with JNK activation, the level of phos-
pho–c-Jun in activated HUVECs underwent marked in-
crease after PEDF treatment (unpublished data).
In vitro, JNK immunocomplexes from the extracts of
resting ECs were able to phosphorylate exogenous GST-
NFATc2 substrate. When isolated from bFGF-stimulated
cells, similar complexes showed lower GST-NFATc2 phos-
phorylating activity. PEDF alone had no effect on the basal
NFAT phosphorylation ability, but completely restored
NFAT phosphorylation by JNK complexes in bFGF-
induced cells (Fig. 2 d).
PEDF-dependent increase in the NFATc2 phosphoryla-
tion and cytoplasmic retention in the activated ECs were
driven by JNK kinases because both were blocked by
SP600125, an inhibitor of multiple JNK isoforms (Fig. 2, c
Figure 1. NFAT deactivation by PEDF.
(a) NFAT dephosphorylation by bFGF. Cell
extracts of bFGF-induced human microvascu-
lar ECs (5 ng/ml, 15 min) were precipitated
with phosphoserine antibody and analyzed
by immunoblotting with NFATc2 antibody.
Note the decreased NFATc2 phosphorylation
in the presence of bFGF. (b) PEDF restored
NFATc2 phosphorylation in activated ECs.
VEGF- or bFGF-stimulated ECs were
treated with PEDF (10 nM, 15 min). Note
the decrease in phospho-NFATc2 by an-
giogenic stimuli and higher phosphorylation
levels in the activated cells exposed to inhibi-
tory PEDF. (c and d) Inhibition of NFATc2
nuclear localization by PEDF. HUVECs
grown on gelatinized coverslips were treated
with 200 pg/ml VEGF or 5 ng/ml bFGF
and 10 nM PEDF and stained for NFATc2.
Note the predominance of the cells with
nuclear NFATc2 in the presence of bFGF
or VEGF compared with untreated control
and cytoplasmic NFATc2 localization in the
presence of PEDF. The data were quanti-
fied using MetaView software package (d). 
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and e). SB203580, a p38 inhibitor had no effect (unpub-
lished data).
 
JNK-2–mediated NFATc2 Cytoplasmic Retention, JNK-1
and JNK-2 Contributed To Nuclear Export.
 
SP600125 in-
hibits all JNK isoforms; thus, its ability to oppose PEDF ef-
fects on NFAT phosphorylation and subcellular localization
may be attributed to any of the JNK species. Western blots
probed with phospho-specific JNK antibody or with total
JNK antibody showed protein bands with molecular mass
consistent with JNK-1 or -2, but not JNK-3 (Fig. 2 b).
To determine whether NFATc2 is a direct target for JNK
kinases, we performed immunoprecipitation with antibod-
ies, which discriminate between JNK-1 and JNK-2, using
cytoplasmic or nuclear EC fractions. Resulting protein
complexes were analyzed by Western blot with NFATc2
polyclonal antibodies. To confirm the purity of subcellular
fractions, we reprobed the same blots with GM130 antibod-
ies for Golgi matrix protein (Fig. 2, f and g).
We detected direct interaction of JNK-2 with NFATc2
in the cytoplasm. In resting ECs, JNK-2–NFATc2 com-
plexes were present at low steady-state levels, which were
further reduced by bFGF and VEGF. PEDF treatment
caused a weak increase in JNK-2 bound NFATc2 in quies-
cent ECs; however, combined with VEGF or with bFGF,
PEDF caused a 
 
 20-fold increase of NFATc2/JNK-2 as-
sociation (Fig. 2 f). No detectable complexes between
NFATc2 and JNK1 were observed in the cytoplasm (un-
published data).
In the nuclei, NFATc2 was bound at low levels to both
JNK-1 and JNK-2 in resting ECs. This binding was de-
creased by both VEGF and bFGF (Fig. 2 g). PEDF dra-
matically increased JNK1–NFATc2 interaction in bFGF-
stimulated cells and improved complex formation in
VEGF-stimulated ones. Nuclear NFATc2–JNK-2 com-
plexes were also increased in PEDF-dependent manner
upon activation with bFGF (Fig. 2 g).
JNK Was Critical for Apoptosis and Antiangiogenesis by
PEDF In Vitro and In Vivo. To test functional signifi-
cance of JNK-dependent NFAT deactivation by PEDF, we
examined the effect of SP600125 on the EC apoptosis.
Figure 2. The role of JNK kinases in
NFATc2 deactivation by PEDF. (a) PEDF
failed to activate p38MAPK or Erk1/2 ki-
nases. Confluent HUVECs were stimulated
with 200 pg/ml VEGF or 5 ng/ml bFGF.
10 nM PEDF was added where indicated.
Cell extracts were analyzed by Western
blotting with antibodies for active phos-
phorylated forms of Erk1/2 (p-Erk) and for
dually phosphorylated p38 (pp38). The blots
were reprobed for total Erk and p38 to en-
sure equal loading. The representative result
of three independent experiments is shown.
(b) PEDF enhanced JNK activation in stim-
ulated ECs. HUVECs were treated as indi-
cated with VEGF or bFGF   PEDF for 15
min. Cell extracts were resolved by SDS-
PAGE and analyzed by Western blotting
with antibodies for active, dually phosphor-
ylated JNK (top, ppJNK) or total JNK (bot-
tom) as a loading control. Three indepen-
dent experiments were performed with
similar results. (c) PEDF-dependent NFATc2
phosphorylation required JNK kinases.
VEGF-stimulated HUVECs were treated
with PEDF alone or in combination with
100 nM of SP600125, a generic JNK inhib-
itor. Cell lysates were immunoprecipitated
with phosphoserine antibody and analyzed
by Western blotting with NFATc2 antibody.
Note the increase in NFATc2 phosphoryla-
tion by PEDF in stimulated ECs and its at-
tenuation in the presence of JNK inhibitor.
(d) Increased JNK activity in PEDF-treated
cells. HUVECs were treated with bFGF (15 min, 5 ng/ml) and/or PEDF, and JNK activity was assessed by immunocomplex kinase assay with exoge-
nous recombinant GST-NFATc2 substrate. Note the decrease in JNK activity in bFGF-treated ECs and the capacity for NFATc2 phosphorylation in
cells treated with bFGF   PEDF. Western blot with JNK antibodies was performed to ensure equal loading. The result is representative of three inde-
pendent experiments. (e) NFATc2 redistribution by PEDF was JNK dependent. HUVECs were plated on gelatinized coverslips; treated with indicated
combinations of VEGF, PEDF, and JNK inhibitor SP600125; and stained for NFATc2. JNK blockade caused persistent NFATc2 nuclear localization
(active state) despite PEDF treatment. (f and g) PEDF caused physical interaction between JNK and NFATc2. Quiescent or activated HUVECs (induced
with VEGF or bFGF, as indicated) were treated for 15 min with PEDF. Nuclear or cytosolic extracts were precipitated with JNK-1– or JNK-2–specific
antibody and analyzed by Western blotting with NFATc2 pAb. Purity of the fractions was determined by blotting with antibodies against GM130 protein.
(f) PEDF increased interaction between JNK-2 and NFATc2 in the cytosol of stimulated ECs. (g) NFATc2 interacted with both JNK-1 and JNK-2 in
the nuclei; note the increased complex formation by PEDF in stimulated but not in quiescent ECs.NFAT Regulates Angiogenic Balance 1518
Increasing concentrations of SP600125 slightly increased
background EC apoptosis in the presence of bFGF alone.
However, in bFGF-stimulated cells, apoptosis by PEDF
was decreased in a dose-dependent manner by the same in-
hibitor concentrations (Fig. 3 a).
In vitro, increased EC chemotaxis up the gradient of an-
giogenic stimuli reflects in vivo angiogenic response (41).
When tested in the migration assay, SP600125 had no ef-
fect on background random EC migration in serum-free
medium, or on VEGF-induced migration. However, it
drastically reduced the inhibitory effect of PEDF (Fig. 3 b).
In vivo, in corneal neovascularization assay mice devel-
oped an adequate angiogenic response to bFGF despite the
presence of JNK inhibitor; however, SP600125 severely
impaired the inhibitory activity of PEDF (Fig. 3, c and d).
Combined, our results demonstrate that JNK kinases are
crucial for PEDF antiangiogenic signaling.
PEDF Decreased NFAT DNA Binding Activity and Blocked
c-FLIP Gene Transcription by NFAT in the Activated Endothe-
lium. To evaluate PEDF effect on NFAT binding to the
cognate DNA sequences, we used EMSA with the dual
NFAT consensus binding site from the IL-2 promoter (36,
42). bFGF induced NFATc2 binding to a specific oligo-
nucleotide, which was reduced in the presence of unla-
beled specific oligonucleotide, but not in the presence of
the nonspecific oligonucleotide containing a binding site
for SP-1. NFAT antibody induced supershift in mobility
of the DNA–NFATc2 complexes. Predictably, PEDF re-
versed increased NFAT DNA binding in activated ECs
(Fig. 4 a).
We have shown previously that apoptosis due to angio-
genesis inhibitors involves caspase-8 activation and down-
regulation of c-FLIP, an endogenous caspase-8 inhibitor
(5). We sought the NFATc2 role in the regulation of
c-FLIP by PEDF. Decrease in c-FLIP protein in the activated
ECs was detectable and reversible by the pretreatment with
JNK inhibitor (Fig. 4 b). Using semi-quantitative RT-
PCR, we observed significant down-regulation of c-FLIP
message due to PEDF in bFGF-stimulated ECs (Fig. 4 c).
The 5  flanking region of c-FLIP promoter contains
three putative consensus NFAT sites at positions 370, 751,
and 862. To determine whether c-FLIP down-regulation
of PEDF occurred at the transcription initiation and to
confirm the role of NFATc2, we performed ChIP assay of
an  382 bp region of the c-FLIP promoter. ChIP revealed
direct NFATc2 interaction with c-FLIP promoter chroma-
tin of the activated ECs, which was strongly decreased by
PEDF (Fig. 4, d and e).
Discussion
The growing body of evidence strongly supports the hy-
pothesis where the balance between EC survival and apopto-
sis determines angiogenesis versus maintenance or regression
of existing capillaries (2). Survival and apoptosis are them-
selves determined by the extracellular signals from angiogen-
esis inhibitors and stimuli (43, 44). Recent studies indicate
that survival and apoptotic cascades occur simultaneously
within a single cell with mutually dependent outcomes. In
other words, cross-talk between the inhibitory and stimula-
Figure 3. JNK inhibitor attenuated EC apoptosis by
PEDF and interfered with its antiangiogenic activity.
(a) PEDF-induced apoptosis was JNK dependent.
HUVECs were treated with bFGF to maintain survival
and with PEDF and/or JNK inhibitor SP600125 for
18 h. Cells positive for DNA fragmentation (apoptosis)
were detected by in situ TUNEL assay and quantified
using MetaView software. The data from two indepen-
dent experiments are presented. (white bars) bFGF
alone. (black bars) bFGF   PEDF. SEM are shown. *,
Significantly different from background (P   0.005).
**, No significant difference from background (P   0.25).
(b) PEDF inhibited EC migration via JNK kinases.
JNK inhibitor was used in the EC chemotaxis assay.
Note that PEDF ability to block migration up the
VEGF gradient was abolished by SP500125. (gray bars)
VEGF alone. (black bars) VEGF   PEDF. *, Signifi-
cant difference from VEGF-induced migration (P  
0.05). (c and d) JNK kinases were essential to PEDF
antiangiogenic activity in vivo. Mice received corneal
implants containing indicated combinations of bFGF,
PEDF, and SP600125. Vascularization was examined
by slit-lamp microscopy. Multiple capillaries reaching
implants were scored as a positive response, and the
data were presented as the number of positive corneas
out of the total implanted (c). SP600125 was neutral
alone and had no effect on bFGF-induced angiogenesis,
but reversed PEDF inhibitory activity. Photographs of
representative corneas are shown (d).Zaichuk et al. 1519
tory signals is an integral part of angiogenic balance in which
stimulated ECs become susceptible to apoptosis by inhibi-
tors. The induction of CD95/Fas by angiogenic stimuli, to
become available for ligation by the inhibitor-generated
CD95L, is the first example of such interplay (5).
Here, we identified a convergence point between pro-
and antiangiogenic signals. Previous studies by other labs
and ours demonstrate NFATc2 requirement for the angio-
genesis by VEGF (25) and possibly by insulin-like growth
factor 1 (45). We added another angiogenic factor, bFGF,
to this list, thereby stressing the central role of NFAT in
vascular remodeling and the likelihood of its targeting by
inhibitors. We showed that NFATc2 activation was dis-
rupted by antiangiogenic PEDF exclusively in stimulated
ECs, whereas basal NFATc2 phosphorylation in quiescent
cells by the same inhibitors was completely unaffected.
This observation indicates NFATc2 as a point of cross-reg-
ulation between inducing and inhibitory angiogenic signal-
ing cascades.
Although NFATs are primarily involved in immune re-
sponse (T cell activation), they are important in other cell
types where they serve such diverse functions as survival,
cell cycle progression, proliferation invasion, and transfor-
mation (10, 12, 46, 47) that could be important in an-
giogenic ECs. NFAT factors are involved in complex
functions of cardiovascular system, pathological cardiac hy-
pertrophy, and vascular development and patterning (48,
49). NFAT activation in immune and other tissues is cal-
cineurin dependent with the exception of constitutively
active NFAT5 (13, 23, 50), and is triggered by multiple
signals including TCR ligation, CD28, and chemokine sig-
naling. NFAT activation and nuclear localization can also
be signaled via integrin  6 4 (46) and by growth factors,
neurotrophic factors, and prostaglandins (45, 51–55).
Distinct NFAT family members are expressed in distinct
tissues (13, 16, 23). Information regarding NFAT represen-
tation and function in the ECs is limited; NFATc2 is in-
duced in ECs upon activation by VEGF; an unspecified
NFAT family member is induced by oxidized phospholip-
ids and insulin-like growth factor 1 (25, 32, 56, 57).
NFAT participation in angiogenesis is little explored;
more attention has been given to its role in vasculogenesis
(15, 48, 58). Even less is known of NFAT transcriptional
targets involved in either vascular development or angio-
genesis regulation with the exception of Cox-2, an impor-
tant mediator of prostaglandin production and angiogenesis
(25, 27, 59). Among known NFAT targets that potentially
contribute to angiogenesis are secreted factors such as cyto-
kines IL-2, IL-4, and GM-CSF (60, 61) and tissue factor
(32). NFAT also affects cell cycle regulatory molecules,
which if modulated in ECs may affect capillary growth.
This includes NFAT induction of cyclin expression and
down-regulation of p21 and p27 (negative cell cycle regu-
lators; reference 17).
We discovered that c-FLIP, a previously unknown
NFAT target, mediates its effects on angiogenesis. c-FLIP
involvement in the EC survival and angiogenesis was de-
scribed previously (5, 62, 63). The attenuation of FLIP
down-regulation by an inhibitor of JNK, an NFAT reg-
ulatory kinase, provided a link between NFAT and
FLIP, whereas ChIP yielded direct evidence of increased
NFATc2 interaction with endogenous c-FLIP promoter in
activated ECs. This interaction was dramatically reduced by
antiangiogenic PEDF. Interestingly, PEDF treatment had
no effect on FLIP levels in quiescent endothelium, thus un-
derscoring the importance of the cross-talk between angio-
genesis inhibitors and stimuli.
To explore upstream regulatory molecules used in
NFATc2 regulation by PEDF, we screened known deacti-
vating kinases that maintain NFAT cytoplasmic localization
by phosphorylation of two or more of the multiple serine
clusters. In vitro NFAT activation can be blocked by Erk1
Figure 4. PEDF decreased NFAT binding to DNA consensus
sequences and to c-FLIP promoter. (a) PEDF treatment lowered
NFATc2 DNA-binding activity in stimulated ECs. HUVECs
were treated for 1 h with indicated combinations of bFGF and
PEDF, and nuclear extracts were examined by EMSA with
NFAT consensus oligonucleotide (ODN). The same ODN
( 10 excess, unlabeled) was used as a specific competitor and
SP1 consensus ODN was used as a nonspecific competitor.
Note the strong decrease in specific band intensity in the presence
of PEDF, the supershift in the presence of NFATc2 antibody,
and the decreased intensity of the supershifted band due to
PEDF. (b–e) c-FLIP regulation by PEDF. VEGF- or bFGF-
induced HUVECs were treated for 4 h (b and c) or 2 h (d and
e) with PEDF alone or in combination with SP600125 and
used for Western blotting for c-FLIP protein (b), for semi-
quantitative RT-PCR for c-FLIP mRNA (c), or in chromatin
ChIP assay (d and e). (b) Note the decreased c-FLIP protein
due to PEDF, and the reversal by SP600125. (c) PEDF de-
creased c-FLIP mRNA in stimulated ECs. Three independent
experiments were performed with similar results. (d and e)
PEDF decreased NFAT binding to c-FLIP promoter in vivo.
ChIP with NFATc2 antibody was performed on ECs activated
with VEGF (d) or bFGF (e) treated with PEDF. Note the
dramatic decrease in the PCR-amplified DNA fragment in the
presence of PEDF.NFAT Regulates Angiogenic Balance 1520
and 2, p38 (21, 64), and several JNK family members (18,
22). In vivo, two types of NFAT deactivation are seen,
constitutive and inducible. Constitutive NFAT phosphory-
lation is mediated via glycogen synthase kinase-3 (20),
casein kinase 1 (19), and JNK-2 (65, 66), resulting in its
nuclear export assisted by Crm1. Inducible deactivation in
response to environmental signals may be mediated by
JNK1, JNK2 (67), or by p38 (68).
We focused on MAP kinases as likely mediators of
NFAT activity elicited by angiogenesis inhibitors. The
MAPKs participate in essential signal transduction involved
in cell growth, differentiation, apoptosis, and transforma-
tion (69). The outcome of JNK activation depends on du-
ration of the signal where sustained long-term response is
associated with proliferation and survival, whereas a short,
transient response is linked to apoptosis and cell cycle arrest
(70). Angiogenic stimuli caused moderate induction of
Erk1/2, p38, and JNK. However, neither Erk1/2 nor p38
induction were affected by angiogenesis inhibitors. On the
contrary, JNK activity was subject to PEDF regulation; we
observed a dramatic increase in phospho-JNK levels and
JNK-dependent substrate phosphorylation by PEDF exclu-
sively in activated ECs. SP600125, a generic JNK inhibitor,
reduced NFATc2 phosphorylation and restored nuclear lo-
calization in affected ECs. The same compound had no ef-
fect on VEGF or bFGF-dependent angiogenesis, but de-
stroyed response to PEDF in vitro and in vivo, pointing to
JNK kinases and their downstream targets as critical ele-
ments of PEDF angioinhibitory signaling.
Once activated, Jun kinases trigger biological responses
by phosphorylating targets that, in turn, regulate transcrip-
tional events or are directly involved in apoptosis. In vivo
gene targeting in mouse models has revealed a critical JNK
role in phosphorylation of AP-1, p53, c-Myc, Bcl-2, and
NFAT (71). However, the contribution of distinct JNK
family members is difficult to evaluate because crossbreed-
ing of mice null for the individual JNK kinases leads to
embryonic lethality, whereas biochemical inhibitors are
relatively unspecific. Some studies point out distinctions
between JNK-1 and JNK-2. Remarkably, NFAT deac-
tivation is one of the points where JNK-1 and JNK-2
functions diverge; whereas both JNK-1 and -2 are impor-
tant for NFATc2 nuclear export in cardiomyocytes (67),
NFATc2 nuclear export in vascular smooth muscle cells is
driven by JNK-2 (65, 66).
As JNK null mice were unavailable, we sought physical
interactions between respective JNK kinases and NFATc2.
We demonstrated direct physical interaction of endogenous
NFATc2 with both JNK-1 and JNK-2. However, only
nuclear NFATc2 was associated with JNK-1, whereas
NFATc2–JNK-2 complexes were both nuclear and cyto-
plasmic. Thus, it is likely that JNK-1 is only involved in
nuclear export, whereas JNK-2 participates in both nuclear
export and cytoplasmic retention of NFATc2. Our results
highlight the interplay between influences that regulate an-
giogenesis by promoting and opposing NFATc2 nuclear
accumulation in ECs.
This is one of the first examples in which transcription
factors were studied downstream of the angiogenesis effec-
tor. Rather, the attention has been focused on transcriptional
regulation of the production of inhibitors and stimuli by the
nonECs as means to manipulate angiogenic switch (72–74).
The only transcription factors known to be regulated by the
effectors of angiogenesis aside from NFAT are NF- B and
GATA (75, 76). Together, our data shed new light on the
fundamental aspects of angiogenesis, provide the first attempt
to uncover transcriptional events elicited by angiogenesis in-
hibitors, and point new directions in the exploration of an-
giogenesis regulation in its extreme complexity.
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